Biotech is the only sector where the primary document is a scientific paper.
Every other sector hands investors a language they already speak — revenue, margin, guidance. Biotech hands them a survival curve and a p-value. FuzeBio exists to close that gap.
The information is public. The comprehension isn't.
Almost everything that moves a biotech stock is disclosed in public before it moves it. Trial registrations, protocol amendments, enrollment updates, advisory committee calendars, competitor readouts — all of it sits in databases anyone can open.
That is not the barrier. The barrier is that reading it correctly takes a vocabulary most investors never had a reason to build. A hazard ratio of 0.62 is either a company-making result or a rounding error depending on the control arm, the powering, and what the competition already showed. Institutional desks solve this by hiring people with doctorates. Retail investors solve it by avoiding the sector, or by buying the headline and finding out later.
Large language models are unusually good at exactly this job — not at predicting markets, but at reading a dense technical document and explaining what it says. FuzeBio is that capability pointed at one industry, wired to live sources, and wrapped in the structure an investor actually needs: a thesis, a fair value, and a date.
Same public record. Different reading speed.
FuzeBio has no private data and claims no informational edge. Every source below is one you could open yourself — the difference is that our agents read all of them for every company, on request, and show you where each claim landed.
SEC EDGAR
10-K, 10-Q and 8-K filings, and the cash and burn figures inside them.
ClinicalTrials.gov
Trial phase, endpoints, enrollment status, and expected completion dates.
FDA databases
Approval history, PDUFA dates, advisory committee schedules.
PubMed and conference abstracts
Mechanism of action, published efficacy and safety data.
Company disclosures
Press releases, pipeline updates, and guidance, as published.
Market data feeds
Price, market cap, volume, and analyst coverage.
Valuations use the methods sell-side analysts use for the same companies — risk-adjusted NPV per pipeline drug, discounted cash flow, and comparable multiples. The formulas, the default probabilities, and the discount rates are all published on our methodology page, not held back as proprietary.
What FuzeBio doesn't do.
Worth stating plainly, because a tool that writes confident sentences about your money should be equally clear about where its confidence stops.
We don’t tell you what to buy
FuzeBio produces research, not recommendations, allocations, or price targets you should act on unexamined. We are not registered investment advisers and nothing on the platform is advice.
We don’t claim to predict readouts
No one can tell you whether a Phase 3 will hit. What we can do is show you the design, the endpoint, the enrollment, and the base rates — so your own estimate is an informed one.
We don’t hide the assumptions
Every valuation depends on inputs someone chose. Ours are visible and editable rather than baked into a number. If you disagree with a probability of success, change it and watch what happens.
We don’t fill gaps with guesses
When a company hasn’t disclosed something, the report says the data isn’t available. An empty field is more useful than a confident invention.
Judge it on a company you know.
The fastest way to test any research product is to point it at something you already understand and see whether it earns its place.